Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Tremfya Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The expansion observed during the historical timeframe was driven by a rising incidence of psoriasis and psoriatic arthritis, the proven efficacy of biologic treatments, the broadening scope of specialized dermatological services, enhanced patient compliance with biologic regimens, and more extensive insurance reimbursement for such medications.
Growth during the forecast period is driven by a rising need for sustained inflammatory disease control, the broader application of biologics within gastroenterology, a growing inclination toward dosing schedules that require fewer administrations, heightened investment in monoclonal antibody development, and an intensified emphasis on tailored immunology treatments. Key developments shaping this period include the expanding utilization of IL-23 inhibitors, increased demand for biologics with prolonged dosing intervals, an extension of approved autoimmune conditions, a surge in the use of subcutaneous biologic formulations, and a stronger commitment to precise immunomodulation strategies.
Download A Free Sample Report For Comprehensive Market Insights:
Tremfya Market Industry Drivers: What Is Driving Revenue Growth?
The anticipated expansion of the tremfya market is being driven forward by the growing occurrence of autoimmune disorders. These disorders are characterized by the immune system mistakenly attacking the body’s own cells, tissues, or organs, viewing them as foreign intruders. Factors fueling this rise include genetic susceptibility, environmental triggers, shifts in lifestyle, heightened public awareness, and enhanced diagnostic tools. Tremfya functions as a monoclonal antibody that targets interleukin-23 (IL-23), working to regulate the immune system’s excessive activity, decrease inflammation, and relieve symptoms in conditions like psoriasis and psoriatic arthritis. To illustrate, the Arthritis Australia, a non-profit organization based in Australia, reported in February 2024 that an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) by 2025, with these figures anticipated to climb to about 280,040 males and 479,828 females by 2040. Consequently, the rising incidence of autoimmune diseases is fueling the growth of the tremfya market.
A surge in healthcare spending is expected to drive the tremfya market forward in the coming period. This spending encompasses all funds directed toward medical services, products, and public health efforts aimed at preserving and enhancing well-being. The uptick is largely attributed to an aging population that demands more medical attention, along with the increasing prevalence of chronic conditions, such as diabetes and heart disease. Elevated healthcare expenditure facilitates greater access to advanced biologic treatments like tremfya by improving reimbursement policies, boosting diagnosis rates, and making therapies more affordable for patients. For instance, the Centers for Medicare & Medicaid Services, a US agency overseeing Medicare and Medicaid programs, noted in December 2024 that U.S. healthcare spending rose by 7.5% in 2023, reaching $4.9 trillion, approximately $14,570 per person. Thus, increasing healthcare expenditure is propelling the tremfya market’s growth.
Tremfya Market Segments: Where Are The Largest Growth Opportunities?
The tremfya market covered in this report is segmented –
1) By Indication: Moderate-To-Severe Plaque Psoriasis, Active PsA
2) By Formulation: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By End User: Adult Patients, Geriatric Patients
Tremfya Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the Tremfya market are securing regulatory approvals that broaden the drug’s approved treatment indications, including moderate-to-severe Crohn’s disease, thus expanding the addressable patient population and commercial opportunity. Regulatory approvals are the official permissions granted by bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), which allow a medicine to be marketed for specific indications once its safety, effectiveness, and quality have been proven. For example, in September 2024, the pharmaceutical company Johnson & Johnson, headquartered in the United States, obtained FDA clearance for TREMFYA (guselkumab) to treat adults with moderately to severely active ulcerative colitis, making it the first dual-acting interleukin-23 inhibitor approved for this indication. This approval was supported by favorable outcomes from the Phase 2b/3 QUASAR trial, where around half of the patients experienced clinical remission following 44 weeks of therapy. TREMFYA works by targeting interleukin-23, which aids in normalizing the inflammatory response within the colon.
Tremfya Market Major Participants And Competitive Dynamics
Major companies operating in the tremfya market are Johnson & Johnson
Access The Complete Tremfya Market Report:
Tremfya Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the tremfy market in 2025. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model